ACT Capital Management LLC Takes $4.98 Million Position in Arrowhead Pharmaceuticals, Inc. $ARWR

ACT Capital Management LLC bought a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 4th quarter, HoldingsChannel.com reports. The firm bought 75,000 shares of the biotechnology company’s stock, valued at approximately $4,979,000. Arrowhead Pharmaceuticals comprises approximately 4.0% of ACT Capital Management LLC’s holdings, making the stock its 10th biggest holding.

A number of other institutional investors have also recently added to or reduced their stakes in ARWR. Royal Bank of Canada lifted its position in Arrowhead Pharmaceuticals by 30.2% during the first quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company’s stock worth $576,000 after buying an additional 10,496 shares in the last quarter. AQR Capital Management LLC purchased a new position in Arrowhead Pharmaceuticals during the first quarter worth approximately $514,000. Goldman Sachs Group Inc. lifted its position in Arrowhead Pharmaceuticals by 34.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after buying an additional 447,456 shares in the last quarter. Empowered Funds LLC lifted its position in Arrowhead Pharmaceuticals by 6.9% during the first quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock worth $194,000 after buying an additional 979 shares in the last quarter. Finally, Focus Partners Wealth raised its position in Arrowhead Pharmaceuticals by 1,339.5% in the first quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company’s stock valued at $207,000 after purchasing an additional 15,123 shares during the period. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ARWR shares. Weiss Ratings downgraded Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Wednesday, May 20th. Wall Street Zen downgraded Arrowhead Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. JPMorgan Chase & Co. started coverage on Arrowhead Pharmaceuticals in a research report on Friday, May 1st. They issued an “overweight” rating and a $88.00 target price on the stock. Finally, Royal Bank Of Canada lifted their target price on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $86.36.

Insider Buying and Selling

In related news, insider James C. Hamilton sold 10,000 shares of the business’s stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total transaction of $750,000.00. Following the completion of the transaction, the insider directly owned 226,958 shares of the company’s stock, valued at $17,021,850. The trade was a 4.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the business’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total value of $934,328.25. Following the transaction, the chief financial officer directly owned 162,905 shares of the company’s stock, valued at $11,623,271.75. The trade was a 7.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 26,065 shares of company stock valued at $1,912,662 in the last three months. 3.60% of the stock is owned by corporate insiders.

Arrowhead Pharmaceuticals Trading Up 5.9%

ARWR opened at $81.04 on Thursday. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $14.30 and a 12 month high of $82.48. The stock has a market capitalization of $11.42 billion, a price-to-earnings ratio of -37.69 and a beta of 1.28. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23. The business has a fifty day moving average price of $73.49 and a 200 day moving average price of $67.37.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The firm had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. During the same period in the previous year, the firm posted $2.75 EPS. Arrowhead Pharmaceuticals’s revenue for the quarter was down 86.4% on a year-over-year basis. Sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.